Send to

Choose Destination
Atherosclerosis. 2014 Dec;237(2):584-8. doi: 10.1016/j.atherosclerosis.2014.10.023. Epub 2014 Oct 18.

Combined lowering of low grade systemic inflammation and insulin resistance in metabolic syndrome patients treated with Ginkgo biloba.

Author information

Charité - University Clinic Berlin, 10117 Berlin, Germany; University of Uppsala Biomedical Center, 751 23 Uppsala, Sweden. Electronic address:
Charité - University Clinic Berlin, 10117 Berlin, Germany.
Swiss Analysis AG, 8274 Tägerwilen, Switzerland.
Charité - University Clinic Berlin, 10117 Berlin, Germany; Scienion AG, 12489 Berlin, Germany.


In a clinical pilot study with eleven metabolic syndrome patients, a simultaneous decrease in hs-CRP from 8.85 ± 4.09 to 4.92 ± 2.51 mg/L (-44.4%) (p < 0.0436) and HOMA-IR from 3.07 ± 0.63 to 2.60 ± 0.51 mU/L × mg/dL (-15.3%) (p < 0.0120) as well as a beneficial change of arteriosclerotic, inflammatory and oxidative stress biomarkers were detected after 2-month treatment with Ginkgo biloba. Furthermore, both IL-6 (-12.9%, p < 0.0407) and nanoplaque formation (-14.3%, p < 0.0077) were additionally reduced. According to a large clinical trial elucidating the importance of insulin resistance and low-grade systemic inflammation for cardiovascular disease and overall mortality risk, these data might indicate a CVD/total mortality risk reduction.


CVD/total mortality risk; Ginkgo biloba; High-sensitivity C-reactive protein (hs-CRP); Homeostasis model assessment of insulin resistance (HOMA-IR); Metabolic syndrome patients

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center